title: Treatment with type-2 selective and non-selective cyclooxygenase inhibitors improves T-cell proliferation in HIV-infected patients on highly active antiretroviral therapy.
authors.affiliation: The Biotechnology Centre of Oslo, N-0317 Oslo, Norway.
authors.forename: C Christian
authors.initials: CC
authors.lastname: Johansson
authors.forename: Tone
authors.initials: T
authors.lastname: Bryn
authors.forename: Einar M
authors.initials: EM
authors.lastname: Aandahl
authors.forename: Maria A
authors.initials: MA
authors.lastname: Areklett
authors.forename: Pål
authors.initials: P
authors.lastname: Aukrust
authors.forename: Kjetil
authors.initials: K
authors.lastname: Taskén
authors.forename: Stig S
authors.initials: SS
authors.lastname: Frøland
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D002455:Cell Division; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use*; D007783:Lactones / Q000627:therapeutic use*; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D013450:Sulfones; D013601:T-Lymphocytes / Q000276:immunology*; D019562:Viral Load
chemical_list: D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib; D007213:Indomethacin